Arvinas Appoints New CMO, Dr. McCluskey
Ticker: ARVN · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1655759
| Field | Detail |
|---|---|
| Company | Arvinas, Inc. (ARVN) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: ARVN
TL;DR
Arvinas just swapped CMOs, bringing in Dr. McCluskey and saying goodbye to Dr. Small.
AI Summary
On June 15, 2024, Arvinas, Inc. announced the departure of Dr. Robert T. Small from his role as Chief Medical Officer. The company also announced the appointment of Dr. John A. McCluskey as the new Chief Medical Officer, effective immediately. Additionally, the company disclosed compensatory arrangements for Dr. McCluskey.
Why It Matters
A change in a key executive role like Chief Medical Officer can signal shifts in the company's strategic direction or pipeline development.
Risk Assessment
Risk Level: medium — Changes in key executive leadership can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Arvinas, Inc. (company) — Registrant
- Dr. Robert T. Small (person) — Departing Chief Medical Officer
- Dr. John A. McCluskey (person) — Appointed Chief Medical Officer
- June 15, 2024 (date) — Effective date of changes
FAQ
Who is the new Chief Medical Officer at Arvinas?
Dr. John A. McCluskey has been appointed as the new Chief Medical Officer, effective immediately as of June 15, 2024.
Who previously held the Chief Medical Officer position?
Dr. Robert T. Small previously served as the Chief Medical Officer before his departure on June 15, 2024.
What is the effective date of the reported changes?
The earliest event reported is dated June 15, 2024.
What is Arvinas, Inc.'s principal executive office address?
Arvinas, Inc.'s principal executive offices are located at 5 Science Park, 395 Winchester Ave., New Haven, Connecticut 06511.
What is the filing date of this 8-K report?
This 8-K report was filed as of June 17, 2024.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-06-17 07:03:14
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market
Filing Documents
- arvn-20240615.htm (8-K) — 24KB
- 0001655759-24-000091.txt ( ) — 149KB
- arvn-20240615.xsd (EX-101.SCH) — 2KB
- arvn-20240615_lab.xml (EX-101.LAB) — 23KB
- arvn-20240615_pre.xml (EX-101.PRE) — 13KB
- arvn-20240615_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: June 17, 2024 By: /s/ Randy Teel Randy Teel Interim Chief Financial Officer